Complete Genomics

Executive Summary

Complete Genomics is a BIOSECURE-designated genomics sequencing company with dual operations in San Jose and BGI China, making it extremely high-risk for US pharma partnerships. The company specializes in next-generation sequencing technologies and genomic analysis platforms but faces complete market exclusion from US government contracts and likely partner avoidance due to national security concerns. Any BD engagement would require immediate divestiture from BGI or complete operational separation, which appears structurally impossible given the integrated business model. US pharma should avoid engagement unless Complete Genomics undergoes fundamental ownership restructuring.

Structure: Complete Genomics operates with a complex dual-headquarters structure spanning San Jose and BGI China, suggesting either a subsidiary relationship with BGI or shared ownership structure that triggers BIOSECURE designation. The lack of clear subsidiary data indicates potential opacity in ownership chains that would require extensive due diligence to untangle Chinese state-linked exposures. This structural ambiguity itself represents a compliance risk for US partners.